



What is claimed is:

1. A compound having the structure:



or a pharmaceutically acceptable salt, stereoisomer, or a mixture of stereoisomers thereof.

2. A compound of claim 1 having the structure:



or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising the compound claim 1, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or a mixture of stereoisomers thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

4. Use of the pharmaceutical composition of claim 3 for the manufacture of a medicament for treating a disease or condition mediated, at least in part, by LRRK2, wherein the disease or condition is a neurodegenerative disease; Parkinson's disease or dementia; a central nervous system (CNS) disorder; Alzheimer's disease or L-Dopa induced dyskinesia; a cancer; kidney cancer, breast cancer, prostate cancer, blood cancer, papillary cancer, lung cancer, acute myelogenous leukemia, or multiple myeloma; inflammatory disease; leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, or ankylosing spondylitis.

5. Use of a compound of claim 1 or a deuterated analog, tautomer, stereoisomer, or a mixture of stereoisomers thereof, for the manufacture of a medicament for treating a neurodegenerative disease, cancer, an inflammatory disease, Alzheimer's disease, L-Dopa induced dyskinesia, Parkinson's disease, dementia, amyotrophic lateral sclerosis (ALS), kidney cancer, breast cancer, prostate cancer,

blood cancer, papillary cancer, lung cancer, acute myelogenous leukemia, multiple myeloma, leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, or ankylosing spondylitis.

6. The use of claim 5, wherein the disease or condition is a neurodegenerative disease.
7. The use of claim 6, wherein the neurodegenerative disease is Parkinson's disease or dementia.
8. The use of claim 7, wherein the disease or condition is a central nervous system (CNS) disorder.
9. The use of claim 8, wherein the CNS disorder is Alzheimer's disease or L-Dopa induced dyskinesia.
10. The use of claim 5, wherein the disease or condition is a cancer.
11. The use of claim 10, wherein the cancer is kidney cancer, breast cancer, prostate cancer, blood cancer, papillary cancer, lung cancer, acute myelogenous leukemia, or multiple myeloma.
12. The use of claim 5, wherein the disease or condition is an inflammatory disease.
13. The use of claim 12, wherein the inflammatory disease is leprosy, Crohn's disease, inflammatory bowel disease, ulcerative colitis, amyotrophic lateral sclerosis, rheumatoid arthritis, or ankylosing spondylitis.
14. Use of the pharmaceutical composition of claim 3 for the manufacture of a medicament for enhancing cognitive memory.
15. Use of a compound of claim 1, or a deuterated analog, tautomer, stereoisomer, or a mixture of stereoisomers thereof, for the manufacture of a medicament for therapy.